Medical consumables company Poly Medicure Ltd on Tuesday (March 11) announced that it has received Medical Device Regulation (MDR) certification for 54 of its products.These devices cater to multiple medical specialties, including infusion therapy, vascular access, renal care, urology, surgery & wound care, transfusion systems, anaesthesia & respiratory care, gastroenterology, and diagnostics.
The MDR certification ensures that these products comply with the European Union’s stringent safety, quality, and regulatory standards. This milestone strengthens Poly Medicure’s position in the global medical consumables market, reaffirming its commitment to providing high-quality and innovative healthcare solutions.
Also Read: Poly Medicure forms JV with AMPIN C&I Power for Haryana solar projectRishi Baid, Joint Managing Director of Poly Medicure, said, “Polymed has been the largest exporter of consumable medical devices for over a decade now. The MDR certification demonstrates that our products not only meet but exceed the most stringent safety and quality standards. We are steadfast in our commitment to these principles, which are at the core of our growth and success.
The MDR certification ensures that these products comply with the European Union’s stringent safety, quality, and regulatory standards. This milestone strengthens Poly Medicure’s position in the global medical consumables market, reaffirming its commitment to providing high-quality and innovative healthcare solutions.
Also Read: Poly Medicure forms JV with AMPIN C&I Power for Haryana solar projectRishi Baid, Joint Managing Director of Poly Medicure, said, “Polymed has been the largest exporter of consumable medical devices for over a decade now. The MDR certification demonstrates that our products not only meet but exceed the most stringent safety and quality standards. We are steadfast in our commitment to these principles, which are at the core of our growth and success.
With Europe already contributing half of our export revenue, this certification will further strengthen our presence and reputation in the European market. It is a testament to our focus on quality, innovation, and customer satisfaction.”
Shares of Poly Medicure Ltd ended at ₹2,143.95, down by ₹159.15, or 6.91%, on the BSE.
Also Read: Poly Medicure eyes growth in interventional cardiology and expansion in key international markets
